Menopoz: Güncel Yaklaşımlar ve Klinik Perspektifler

Hoffman, B. L., Schorge, J. O., Bradshaw, K. D., et al. (2020). Menopause. In Williams Gynecology (4th ed., pp. 604–628). McGraw-Hill.

North American Menopause Society. (2022). The 2022 hormone therapy position statement. Menopause, 29(7), 767–794. https://doi.org/10.1097/GME.0000000000002028

Portman, D. J., & Gass, M. L. (2014). Genitourinary syndrome of menopause: New terminology. Menopause, 21(10), 1063–1068. https://doi.org/10.1097/GME.0000000000000329

Manson, J. E., Chlebowski, R. T., Stefanick, M. L., et al. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA, 310(13), 1353–1368. https://doi.org/10.1001/jama.2013.278040

Gallagher, J. C. (2007). Effect of early menopause on bone mineral density and fractures. Menopause, 14(3 Pt 2), 567–571.

Pinkerton, J. V., Stovall, D. W., & Kightlinger, R. S. (2009). Advances in the treatment of menopausal symptoms. Women's Health, 5(4), 361–384. https://doi.org/10.2217/WHE.09.27

North American Menopause Society. (2022). Menopause practice: A clinician’s guide (6th ed.).

Farquhar, C., Marjoribanks, J., Lethaby, A., Suckling, J., & Lamberts, Q. (2009). Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews, (2), CD004143. https://doi.org/10.1002/14651858.CD004143.pub3

Marjoribanks, J., Farquhar, C., Roberts, H., & Lethaby, A. (2017). Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews, (1), CD004143. https://doi.org/10.1002/14651858.CD004143.pub5

Freeman, E. W., Sherif, K. (2007). Menopause and hormone replacement therapy. BMJ, 334(7596), 736–741. https://doi.org/10.1136/bmj.39169.418416.BE

Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Kooperberg, C., Stefanick, M. L., ... & Writing Group for the Women's Health Initiative Investigators. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA, 288(3), 321–333. https://doi.org/10.1001/jama.288.3.321

Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015). Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 100(11), 3975–4011. https://doi.org/10.1210/jc.2015-2236

The North American Menopause Society (NAMS). (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767–794. https://doi.org/10.1097/GME.0000000000002028

Fraser, G. L., Lederman, S., Waldbaum, A., Kroll, R., & Beresford, T. (2023). Fezolinetant, a neurokinin 3 receptor antagonist, for moderate-to-severe vasomotor symptoms: A phase 3 RCT. The Lancet, 401(10388), 1230–1239. https://doi.org/10.1016/S0140-6736(23)00475-7

Prague, J. K., Roberts, R. E., Comninos, A. N., et al. (2023). Neurokinin receptor antagonists for menopausal flushing: A review. Journal of Clinical Endocrinology & Metabolism, 108(2), 333–343. https://doi.org/10.1210/clinem/dgac640

Labrie, F., Archer, D. F., Koltun, W., Vachon, A., Young, D., & Frenette, L. (2016). Efficacy of intravaginal DHEA (prasterone) for vulvovaginal atrophy. Menopause, 23(3), 243–250. https://doi.org/10.1097/GME.0000000000000536

Portman, D. J., & Gass, M. L. (2014). Genitourinary syndrome of menopause: New terminology for vulvovaginal atrophy. Menopause, 21(10), 1063–1068. https://doi.org/10.1097/GME.0000000000000329

Chen, F. P., Chien, M. H., & Chan, C. C. (2013). The effectiveness of exercise in relieving menopausal symptoms: A systematic review. Menopause, 20(1), 51–60. https://doi.org/10.1097/GME.0b013e31826ce3d4

Stuenkel, C. A., et al. (2015). Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 100(11), 3975–4011. https://doi.org/10.1210/jc.2015-2236

Santoro, N., Epperson, C. N., & Mathews, S. B. (2015). Menopausal symptoms and their management. Endocrinology and Metabolism Clinics, 44(3), 497–515. https://doi.org/10.1016/j.ecl.2015.05.001

Endocrine Society. (2016). Compounded bioidentical hormone therapy position statement. https://www.endocrine.org

Stuenkel, C. A., et al. (2015). Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 100(11), 3975–4011. https://doi.org/10.1210/jc.2015-2236

American College of Obstetricians and Gynecologists (ACOG). (2012). Compounded bioidentical menopausal hormone therapy. Committee Opinion No. 532.

UpToDate. (2024). Bioidentical hormones for menopausal symptoms. Retrieved from https://www.uptodate.com

Rossouw, J. E., et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA, 288(3), 321–333. https://doi.org/10.1001/jama.288.3.321

Santen, R. J., et al. (2010). Postmenopausal hormone therapy: An Endocrine Society scientific statement. Journal of Clinical Endocrinology & Metabolism, 95(7 Suppl 1), s1–s66. https://doi.org/10.1210/jc.2009-2509

Manson, J. E., et al. (2013). Menopausal hormone therapy and long-term all-cause and cause-specific mortality. JAMA, 310(13), 1353–1368. https://doi.org/10.1001/jama.2013.278040

NAMS. (2017). Management of symptomatic menopause. Menopause, 24(7), 728–753. https://doi.org/10.1097/GME.0000000000000921

Hoffman, B. L., Schorge, J. O., Bradshaw, K. D., et al. (2020). Menopause. In Williams Gynecology (4th ed., pp. 604–628). McGraw-Hill.

North American Menopause Society. (2022). The 2022 hormone therapy position statement. Menopause, 29(7), 767–794. https://doi.org/10.1097/GME.0000000000002028

Portman, D. J., & Gass, M. L. (2014). Genitourinary syndrome of menopause: New terminology. Menopause, 21(10), 1063–1068. https://doi.org/10.1097/GME.0000000000000329

Manson, J. E., Chlebowski, R. T., Stefanick, M. L., et al. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA, 310(13), 1353–1368. https://doi.org/10.1001/jama.2013.278040

Gallagher, J. C. (2007). Effect of early menopause on bone mineral density and fractures. Menopause, 14(3 Pt 2), 567–571.

Pinkerton, J. V., Stovall, D. W., & Kightlinger, R. S. (2009). Advances in the treatment of menopausal symptoms. Women's Health, 5(4), 361–384. https://doi.org/10.2217/WHE.09.27

North American Menopause Society. (2022). Menopause practice: A clinician’s guide (6th ed.).

Farquhar, C., Marjoribanks, J., Lethaby, A., Suckling, J., & Lamberts, Q. (2009). Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews, (2), CD004143. https://doi.org/10.1002/14651858.CD004143.pub3

Marjoribanks, J., Farquhar, C., Roberts, H., & Lethaby, A. (2017). Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews, (1), CD004143. https://doi.org/10.1002/14651858.CD004143.pub5

Freeman, E. W., Sherif, K. (2007). Menopause and hormone replacement therapy. BMJ, 334(7596), 736–741. https://doi.org/10.1136/bmj.39169.418416.BE

Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Kooperberg, C., Stefanick, M. L., ... & Writing Group for the Women's Health Initiative Investigators. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA, 288(3), 321–333. https://doi.org/10.1001/jama.288.3.321

Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015). Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 100(11), 3975–4011. https://doi.org/10.1210/jc.2015-2236

The North American Menopause Society (NAMS). (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767–794. https://doi.org/10.1097/GME.0000000000002028

Fraser, G. L., Lederman, S., Waldbaum, A., Kroll, R., & Beresford, T. (2023). Fezolinetant, a neurokinin 3 receptor antagonist, for moderate-to-severe vasomotor symptoms: A phase 3 RCT. The Lancet, 401(10388), 1230–1239. https://doi.org/10.1016/S0140-6736(23)00475-7

Prague, J. K., Roberts, R. E., Comninos, A. N., et al. (2023). Neurokinin receptor antagonists for menopausal flushing: A review. Journal of Clinical Endocrinology & Metabolism, 108(2), 333–343. https://doi.org/10.1210/clinem/dgac640

Labrie, F., Archer, D. F., Koltun, W., Vachon, A., Young, D., & Frenette, L. (2016). Efficacy of intravaginal DHEA (prasterone) for vulvovaginal atrophy. Menopause, 23(3), 243–250. https://doi.org/10.1097/GME.0000000000000536

Portman, D. J., & Gass, M. L. (2014). Genitourinary syndrome of menopause: New terminology for vulvovaginal atrophy. Menopause, 21(10), 1063–1068. https://doi.org/10.1097/GME.0000000000000329

Chen, F. P., Chien, M. H., & Chan, C. C. (2013). The effectiveness of exercise in relieving menopausal symptoms: A systematic review. Menopause, 20(1), 51–60. https://doi.org/10.1097/GME.0b013e31826ce3d4

Stuenkel, C. A., et al. (2015). Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 100(11), 3975–4011. https://doi.org/10.1210/jc.2015-2236

Santoro, N., Epperson, C. N., & Mathews, S. B. (2015). Menopausal symptoms and their management. Endocrinology and Metabolism Clinics, 44(3), 497–515. https://doi.org/10.1016/j.ecl.2015.05.001

Endocrine Society. (2016). Compounded bioidentical hormone therapy position statement. https://www.endocrine.org

Stuenkel, C. A., et al. (2015). Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 100(11), 3975–4011. https://doi.org/10.1210/jc.2015-2236

American College of Obstetricians and Gynecologists (ACOG). (2012). Compounded bioidentical menopausal hormone therapy. Committee Opinion No. 532.

UpToDate. (2024). Bioidentical hormones for menopausal symptoms. Retrieved from https://www.uptodate.com

Rossouw, J. E., et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA, 288(3), 321–333. https://doi.org/10.1001/jama.288.3.321

Santen, R. J., et al. (2010). Postmenopausal hormone therapy: An Endocrine Society scientific statement. Journal of Clinical Endocrinology & Metabolism, 95(7 Suppl 1), s1–s66. https://doi.org/10.1210/jc.2009-2509

Manson, J. E., et al. (2013). Menopausal hormone therapy and long-term all-cause and cause-specific mortality. JAMA, 310(13), 1353–1368. https://doi.org/10.1001/jama.2013.278040

NAMS. (2017). Management of symptomatic menopause. Menopause, 24(7), 728–753. https://doi.org/10.1097/GME.0000000000000921